News

Kelun-Biotech's A400/EP0031 Advances in NSCLC Treatment Journey

Kelun-Biotech's A400/EP0031 Advances in NSCLC Treatment Journey

Overview of Kelun-Biotech's New Drug Application

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is excited to share that their groundbreaking drug application for A400, also referred to as EP0031, has officially been accepted for review by the National Medical Products Administration (NMPA). This next-generation selective RET inhibitor aims to offer new hope for adult patients suffering from RET-fusion positive non-small cell lung cancer (NSCLC).

Clinical Trials and Efficacy of A400/EP0031

The acceptance of the new drug application (NDA) stems from significant results derived from two pivotal Phase 2 cohorts in the KL400-I/II-01 study. These cohorts explored the efficacy and safety of A400/EP0031 administered at a dosage of 90 mg orally once daily. The trials focused on both patients who have undergone prior treatments and those who are new to treatment.

Results indicated that A400/EP0031 produced encouraging efficacy rates across both patient groups, even for those who had undergone prior immunotherapy or presented with brain metastases. The drug has also shown a promising safety profile, with manageable tolerability, presenting a vital option for this challenging patient population.

CEO Insights on A400/EP0031

Dr. Michael Ge, the CEO of Kelun-Biotech, expressed confidence in the drug's clinical potential, highlighting its status as a tumor-agnostic precision therapy. He noted that this represents a strategic advancement for the company in the solid tumor arena. The team is eager to collaborate closely with regulatory bodies to expedite the review process, aiming to bring A400/EP0031 to patients swiftly.

Understanding RET-fusion Positive NSCLC

RET gene fusions are recognized as a notable subtype of mutations contributing to non-small cell lung cancer. For patients afflicted with RET-fusion positive NSCLC, conventional treatment options offer limited effectiveness, which creates an urgent need for innovative solutions like A400/EP0031. The emergence of selective inhibitors has resulted in incremental improvements in managing advanced cases, albeit facing challenges from RET drug-resistant mutations and associated safety concerns.

The Innovative Drug: A400/EP0031

A400/EP0031 stands out as a promising next-generation selective RET inhibitor specifically designed for conditions such as NSCLC and medullary thyroid cancer (MTC). The company is actively engaged in a Phase 1b/2 clinical trial focused on RET mutations, currently underway.

Notably, the preliminary data from a Phase 1 study of A400/EP0031 presented at a recent annual meeting underscored the drug’s potential effectiveness in treating advanced RET-mutant MTC patients.

Recent Developments in Drug Approval Process

In a move aimed at accelerating the drug’s availability, the FDA granted A400/EP0031 Fast Track designation, opening doors for its progression into Phase 2 clinical developments. Currently, the drug is being analyzed across regions including the United States, the United Kingdom, Europe, and the United Arab Emirates.

About Kelun-Biotech

Kelun-Biotech (6990.HK) operates as a subsidiary of Kelun Pharmaceutical (002422.SZ), concentrating on research, development, manufacturing, and global distribution of innovative biological and small molecule medications. They are committed to addressing high priority health issues—ranging from solid tumors to autoimmune diseases—by developing comprehensive drug solutions for unmet medical needs both within and beyond their local market.

The company’s portfolio includes over 30 key innovative projects, with several already approved for marketing. They continue to lead with initiatives incorporating advanced drug delivery systems, like the proprietary OptiDC™ platform for antibody-drug conjugates (ADC).

Frequently Asked Questions

What is A400/EP0031?

A400/EP0031 is a next-generation selective RET inhibitor developed by Kelun-Biotech, targeting RET-fusion positive NSCLC and other solid tumors.

What role does RET play in NSCLC?

RET gene fusions are critical mutations that contribute to the development of non-small cell lung cancer, often making conventional treatments less effective.

What were the results of the clinical trials for A400/EP0031?

The clinical trials showcased significant efficacy in both treatment-naïve and pre-treated RET-fusion positive NSCLC patients, with a favorable safety profile.

Where is A400/EP0031 currently being tested?

A400/EP0031 is undergoing clinical trials in several regions, including the United States, United Kingdom, Europe, and the United Arab Emirates.

What is Kelun-Biotech's focus?

Kelun-Biotech focuses on the research and development of innovative drugs, emphasizing unmet medical needs across various disease categories, including solid tumors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 6

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 17

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 104

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 67

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Natus Medical Unveils Advanced EMG Software for Enhanced Use

Updated Category News Views 116

Natus Medical's Latest EMG Software Release Natus Medical Incorporated is excited to announce the launch of its newest edition of the Natus Elite EMG software. This software continues to set a high standard in the neurodiagnostic field, delivering both familiarity and reliability that users have come to expect. What makes this release particularly noteworthy is the...

Continue Reading
Toll Brothers Unveils New Luxury Homes in August Park Community

Updated Category News Views 231

Your Dream Home Awaits at August Park Toll Brothers, Inc., a leader in luxury home building, recently announced the launch of an exciting new community known as Toll Brothers at August Park. This neighborhood promises not just high-end living but also a tranquil environment perfect for families and individuals seeking a peaceful lifestyle. Located in a serene area, this...

Continue Reading
Johnny Bigg Expands Presence with New Concessions in Retail

Updated Category News Views 678

Johnny Bigg's Exciting Expansion into Retail Johnny Bigg, a popular fashion brand dedicated to big and tall men, continues to grow its presence in the retail landscape. Recently, the company took a significant step by launching concessions in selected Belk stores. This move marks an important milestone for Johnny Bigg, showcasing its commitment to making fashionable...

Continue Reading
Exploring Sound Investments With Warren Buffett's Wisdom

Updated Category News Views 284

Warren Buffett stood tall as the legendary investor who transformed Berkshire Hathaway into a $1 trillion powerhouse. Back then, this valuation didn’t hinge on flashy products or industry domination. It was all about Buffett’s knack for hunting down stocks that consistently outperformed the market. Berkshire Hathaway's Focused Portfolio: Goldmine or Gimmick? At one...

Continue Reading
Understanding KPIs: A Key to Effective Life Science Marketing

Updated Category News Views 205

Understanding the Importance of KPIs in Life Science Marketing In today's fast-paced life science sector, it's crucial for organizations to utilize data-driven decisions to enhance customer engagement. However, surprisingly, thirty-two percent of marketing and analytics teams in the life sciences report either not knowing about or not using key performance indicators...

Continue Reading